E-postama gönder SITMA AŞILARINDAKİ GELİŞMELER - PROGRESS for MALARIA VACCINES
Öz
Özet: Sıtma tropik ve subtropik bölgelerde önemli bir halk sağlığı sorunu olmaya devam etmektedir. Sıtma ile mücadelede 2000 yılından bu yana mevcut sıtma kontrol önlemlerinin yaygınlaşması ile önemli başarılar elde edilmiştir. Fakat bu önlemlere erişimin kısıtlı olduğu bölgeler bulunması, insektisit ve çoklu ilaç direnci gibi nedenler sıtmayla mücadele ve eliminasyon için sıtmaya karşı etkin bir aşının gerekliliğini ortaya koymaktadır. Günümüzde faz 3 değerlendirmesi yapılmış ve pilot uygulamaya geçmesi planlanan tek aşı RTS,S/AS01 aşısıdır ve diğer aşılardan 5-10 yıl öndedir. Pilot uygulama ile olası eksikliklerin anlaşılıp giderilmesi, gerekirse diğer önlemlerle birleştirilmesi eliminasyon hedefine katkı sağlayacaktır. P. falciparum morbidite ve mortalitesindeki düşüş trendinin sürmesi halinde de önümüzdeki yıllarda çalışmaların P. vivax’a yönelmesi muhtemeldir.
Anahtar sözcükler: Sıtma, Aşı, Pre-Eritrositik Aşılar, Kan-Dönemi Aşılar, Bulaşı Önleyen Aşılar
Abstract: Malaria continues to be a major public health problem in tropical regions. In the struggling against malaria, significant achievements have been obtained with the spread of present malaria control precautions since 2000. Hovewer causes such as existing areas limited access to these precautions and insecticide and multidrug resistance exhibits an effective vaccine against malaria is required for struggling and eliminating malaria. RTS, S / AS01 is only vaccine at phase 3 evaluation has been done and planned to do pilot impelementation and the vaccine is 5-10 years ahead than other vaccines. Understanding and eliminating possible deficiencies with pilot implementation, and if necessary combining with other precautions will contribute the elimination goal. If the trend in declining malaria morbidity and mortality continues, it is likely that research will be directed to P. vivax in coming years.
Key words: Malaria, Vaccine, Pre-Erythrocytic Vaccine, Blood-Phase Vaccine, Vaccine-Preventing Vaccine
Tam Metin:
ARTICLE 4Referanslar
World Health Organization. World Malaria Report 2015. http://apps.who.int/iris/bitstream/10665/200018/1/9789241565158_eng.pdf Erişim tarihi: 09.02.2017
CDC and Malaria. https://www.cdc.gov/malaria/resources/pdf/fsp/cdc_malaria_program_508.pdf Erişim tarihi: 09.02.2017
World Health Organization. (2016). Malaria vaccine: WHO position paper—January 2016. Wkly Epidemiol Rec, 91(4), 33-52.
World Health Organization. Guidelines for the Treatment of Malaria. http://apps.who.int/iris/bitstream/10665/162441/1/9789241549127_eng.pdf Erişim tarihi: 09.02.2017
Schwartz, L., Brown, G. V., Genton, B., & Moorthy, V. S. (2012). A review of malaria vaccine clinical projects based on the WHO rainbow table. Malaria journal, 11(1), 11.
Dondorp, A. M., Nosten, F., Yi, P., Das, D., Phyo, A. P., Tarning, J., ... & Ringwald, P. (2009). Artemisinin resistance in Plasmodium falciparum malaria. New England Journal of Medicine, 361(5), 455-467.
World Health Organization. Background to development of vaccine roadmaps, to include priority areas for research, product development, capacities, and policy and commercialization. http://www.who.int/immunization/research/meetings_workshops/Background_development_vaccine_roadmaps_RSV_mar15.pdf?ua=1. Erişim tarihi: 09.02.2017
World Health Organization . Malarıa Vaccıne Technology Roadmap November 2013 http://www.who.int/immunization/topics/malaria/vaccine_roadmap/TRM_update_nov13.pdf?ua=1. Erişim tarihi: 09.02.2017
Takashima, E., Morita, M., & Tsuboi, T. (2016). Vaccine candidates for malaria: what’s new?. Expert Review of Vaccines, 15:1, 1-3
Karanja, J. K., & Kiboi, N. G. (2016). Current Milestones towards Development of a Fully Deployable Anti-Malaria Vaccine-Future Hope for Malaria-Free World: A Review. J Vaccines Vaccin, 7(332), 2.
Soares, I. D. S., & Rodrigues, M. M. (1998). Malaria vaccine: roadblocks and possible solutions. Brazilian journal of medical and biological research, 31(3), 317-332.
Clyde, D. F. (1990). Immunity to falciparum and vivax malaria induced by irradiated sporozoites: a review of the University of Maryland studies, 1971-75. Bulletin of the World Health Organization, 68(Suppl), 9.
Proietti, C., & Doolan, D. L. (2015). The case for a rational genome-based vaccine against malaria. Frontiers in microbiology, 5:741.
Kuyucu N. ( 2012). Gelecekteki Aşılar. Klinik Gelişim, 25: 44-48.
White, M. T., Verity, R., Griffin, J. T., Asante, K. P., Owusu-Agyei, S., Greenwood, B., ... & Adjei, S. (2015). Immunogenicity of the RTS, S/AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trial. The Lancet infectious diseases, 15(12), 1450-1458.
Carlton, J. M., Sina, B. J., & Adams, J. H. (2011). Why is Plasmodium vivax a neglected tropical disease?. PLoS neglected tropical diseases, 5(6), e1160.
World Health Organization. Tables of malaria vaccine projects globally "The Rainbow Tables". http://www.who.int/immunization/research/development/Rainbow_tables/en/. Erişim tarihi: 09.02.2017.
WHO welcomes global health funding for malaria vaccine. http://www.who.int/mediacentre/news/releases/2016/funding-malaria-vaccine/en/. Erişim tarihi: 09.02.2017.
Rts, S. C. T. P. (2015). Efficacy and safety of RTS, S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. The Lancet, 386(9988), 31-45.
European Medicines Agency First malaria vaccine receives positive scientific opinion from EMA. http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2015/07/WC500190447.pdf Erişim tarihi: 09.02.2017
Questions and answers on RTS,S/ASO1 malaria vaccine. http://www.who.int/immunization/research/development/malaria_vaccine_qa/en/. Erişim tarihi: 09.02.2017.
Refback'ler
- Şu halde refbacks yoktur.